Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. - Wikidata - awgldk - TriplyDB

Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.

Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.

http://www.wikidata.org/entity/Q34407701

about

Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules.Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans.Pseudotype-based neutralization assays for influenza: a systematic analysis.Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)Tuberculosis vaccine development: Shifting focus amid increasing development challenges.Traditional and new influenza vaccines Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.Influenza vaccines: from whole virus preparations to recombinant protein technology.Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.DNA-based influenza vaccines as immunoprophylactic agents toward universality.Live-attenuated auxotrophic mutant of Salmonella Typhimurium expressing immunogenic HA1 protein enhances immunity and protective efficacy against H1N1 influenza virus infection.Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection.A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.Identification of Aim2 as a sensor for DNA vaccines.Future Approaches to DNA Vaccination Against Hemorrhagic Fever Viruses.An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture.A Review of DNA Vaccines Against Influenza Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficiency Virus Type 1 Clade C Envelope Vaccine

P2860

Q30204348-E496FDAB-7765-4D1A-B495-2BA7DF5B3F6F Q30368929-9319E78D-E39D-4DD2-BB7A-7B952FDAB17E Q30372481-D36D0D82-E370-41DE-BF95-B8C32C5691A6 Q30374662-563F09FD-2521-442A-8AE2-E8539BEB3280 Q30375380-FFCBC743-2E33-4F8F-94CA-E3E6ABFBCEF6 Q35055198-4CC3F241-7F5E-48B2-90CF-F4113353CD43 Q35118834-FEF183D6-623C-4514-9F80-EED307944079 Q36256304-C8F0B516-F2F3-420C-B65A-D81ADAD52305 Q37035833-52AB8421-8066-41EC-9023-6294864EB8BF Q37478319-9D95E673-2371-4413-8478-831B5F33D0EE Q37561211-6ABD5BF6-54CD-4659-952B-619254962BBF Q37713895-D866F127-3465-491E-BA2D-89417B7A3042 Q38160083-BED75AFD-CDD3-4D0A-BA64-B5F6F4CF85D3 Q38186768-860310CF-49AD-4D2D-894D-4303BB2FB372 Q38670879-0D022A9F-5291-4318-BF37-4D0F021ADE2E Q38673333-589F1F1D-875F-4D27-BCA1-69DEE33941EC Q38730774-71F613AB-5E2C-4B3C-B737-62F1FD5BD67F Q39079605-EC6CD3E8-2D53-45FE-9856-571229CEC18F Q39373266-AB567272-CC41-41DA-A3E9-1336CCE2CDE2 Q40294097-E14E6F12-A5B5-44EF-8DB0-4FB5E6FA5C7C Q41609361-B6747387-69BD-41F5-BADF-A41E41F5A5B9 Q41922339-9FD70FC5-3C60-44A2-9569-039018F731D1 Q41932790-EC845550-FB89-4BC7-A737-75B8B43DE01B Q42130041-6582B887-109A-4B7C-96F7-4CA333CCA6D0 Q42376121-76EB0F3A-4219-41E0-BD5F-3CA65E439E5F Q47105782-7DB50514-EEB9-4599-BB21-1F03DFD816B4 Q50308620-932FCF5E-29AA-4D01-994F-05AC2ECB1D88 Q57094261-0C641E23-936F-44E3-9C23-EC7591197C1F Q58727008-6A10A13A-BF2C-44EC-9994-02A408CD2399

P2860

Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.

http://www.wikidata.org/entity/Q34407701

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@ast

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@en

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@nl

type

label

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@ast

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@en

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@nl

prefLabel

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@ast

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@en

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@nl

P1433

Q34407701-C494E09A-1447-42F2-ABC1-5FCAEB863F3C

P1476

Q34407701-B7AC53D4-AD39-46C8-8270-E1BE4573F124

P2093

Q34407701-11E38D20-C490-42F0-84FD-B2842FBD3CE0

Q34407701-120F0FEE-EB41-4307-A757-FB9741F2A0D7

Q34407701-227CC736-AA39-49F3-BACF-AEDEC712E79B

Q34407701-3A64573E-2939-4BAF-B033-7F59B9C6F2A5

Q34407701-490DAD90-1A11-4B7E-A015-F87F7CC0D078

Q34407701-60B3D064-1837-47BD-B1D3-70E8DE9855A5

Q34407701-66CE7049-1843-443D-9906-30DD97F9FDF8

Q34407701-7AEE01BA-59E8-420A-A5DD-9F4C3D76A51A

Q34407701-8E89EFBC-6EE7-43BE-B456-7A00482E4F8C

Q34407701-A60A7930-B75D-4630-949B-969616894A17

P2860

Q34407701-005F6F06-59E0-42A4-AD16-26D748A2D75D

Q34407701-02F64035-B355-413B-9BD4-9985C9EB2F0D

Q34407701-0D7B236F-3AFB-4017-84D0-AACA6F6F07DA

Q34407701-2397CC1A-003C-4895-B863-A80BF6FF0AC7

Q34407701-2BC26BF0-C477-4784-A874-CA438C1FFE65

Q34407701-385720A0-26F9-4116-90B9-70F29FF11E32

Q34407701-3EE9197A-85A5-451F-87AB-105C3ED89AE9

Q34407701-4CB29205-C509-4FE2-9B47-53A7FB9A65DD

Q34407701-73D198F4-6A85-4404-A05B-FEE6E4F06DC9

Q34407701-7850C372-95E5-40BF-BE35-DF54A4ADE6BD

P304

Q34407701-20E3876F-AE40-4A21-8ACD-0A11EB6421DF

P31

Q34407701-BE717E47-C00F-488B-876A-456774048B0A

P356

Q34407701-396D81B5-3D51-48F4-A1B8-909AE0428469

P433

Q34407701-10A2FA10-4FE7-4FAB-9700-97B1E7564AA9

P478

Q34407701-46E4BF16-E937-4D64-9821-1DBAC4EBB20C

P577

Q34407701-5725620A-6191-4DEF-9AD7-6EDF916A2CC7

P698

Q34407701-34296CE4-C892-4DF7-A4B6-53D0D5A208D5

P932

Q34407701-54FDC113-8323-45E2-8F55-DA1552E27278

P356

P1433

Clinical and Vaccine Immunology

P1476

Influenza virus h5 DNA vaccina ...... intradermal routes in humans.

@en

P2093

B S Graham

http://www.w3.org/2001/XMLSchema#string

G J Nabel

http://www.w3.org/2001/XMLSchema#string

G Yamshchikov

http://www.w3.org/2001/XMLSchema#string

I J Gordon

http://www.w3.org/2001/XMLSchema#string

J E Ledgerwood

http://www.w3.org/2001/XMLSchema#string

J R Mascola

http://www.w3.org/2001/XMLSchema#string

M B Pearce

http://www.w3.org/2001/XMLSchema#string

M E Enama

http://www.w3.org/2001/XMLSchema#string

R A Koup

http://www.w3.org/2001/XMLSchema#string

R Bailer

http://www.w3.org/2001/XMLSchema#string

P2860

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses.

The origins of pandemic influenza--lessons from the 1918 virus.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.

Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

P304

1792-1797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.05663-11

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22956656

http://www.w3.org/2001/XMLSchema#string

P932

3491556

http://www.w3.org/2001/XMLSchema#string